EUVIMEDScopri EUVIMED
Open access · CC BY-NC-ND 4.0

Cucurbitacin IIb attenuates cancer cachexia induced skeletal muscle atrophy by regulating the IL ‐6/ STAT3 / FoxO signaling pathway

Yaxian Wang, Xipeng Sun, Quanjun Yang, Cheng Guo iD

Phytotherapy Research · 2023-08 · 37 (8) · 3380-3393

DOI: 10.1002/ptr.7811 ↗

At a glance

Journal article in Phytotherapy Research, published online on 2023-04-19. Written by Yaxian Wang and 3 co-authors. Institution: Department of Pharmacy, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. Major MEDLINE topics: Cachexia, Neoplasms. Cited 20 times so far (Crossref); 48 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: National Natural Science Foundation of China.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

The main features of cancer cachexia include skeletal muscle atrophy, which can significantly reduce the quality of life of patients. Clinical treatment of cancer cachexia is mainly based on nutritional therapy and physical exercise; medication only improves appetite but does not reverse the symptoms of skeletal muscle wasting. In this work, we systematically studied the underlying molecular mechanisms by which cucurbitacin IIb (CuIIb) ameliorates muscle wasting in cancer cachexia both in vitro and in vivo. CuIIb significantly ameliorated the chief features of cancer cachexia in vivo, alleviating weight loss, food intake, muscle wasting, adipose tissue depletion, and organ weight reductions. In vitro, CuIIb (10 and 20 μM) dose‐dependently attenuated conditioned medium (CM)‐induced C2C12 myotube atrophy. Collectively, our findings demonstrated that CuIIb prevented the upregulation of the E3 ubiquitin ligase muscle atrophy Fbox protein (MAFbx), myosin heavy chain (MyHC), and myogenin (MyoG) and impacted protein synthesis and degradation. In addition, CuIIb decreased the phosphorylation of Tyr705 in STAT3 by regulating the IL‐6/STAT3/FoxO pathway to reduce skeletal muscle atrophy in cancer cachexia.

Subjects

MeSH terms (MEDLINE)

CachexiaNeoplasmsHumansInterleukin-6Quality of LifeMuscular AtrophySignal TransductionMuscle, SkeletalMuscle Fibers, SkeletalSTAT3 Transcription FactorCucurbitacins

Author keywords

IL-6/STAT3/FoxO pathwaySTAT3cancer cachexiacucurbitacin IIbskeleta muscle atrophy

Substances

Interleukin-6STAT3 Transcription Factorcucurbitacin IIbCucurbitacinsSTAT3 protein, human

Authors and institutions

  • Department of Pharmacy, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

ORCID profiles: Cheng Guo

Funding

  • National Natural Science Foundation of China

Cite

APA

Wang, Y., Sun, X., Yang, Q., & Guo, C. (2023). Cucurbitacin IIb attenuates cancer cachexia induced skeletal muscle atrophy by regulating the IL ‐6/ STAT3 / FoxO signaling pathway. Phytotherapy Research, 37(8), 3380-3393. https://doi.org/10.1002/ptr.7811

Vancouver

Wang Y, Sun X, Yang Q, Guo C. Cucurbitacin IIb attenuates cancer cachexia induced skeletal muscle atrophy by regulating the IL ‐6/ STAT3 / FoxO signaling pathway. Phytotherapy Research. 2023;37(8):3380-3393. doi:10.1002/ptr.7811

BibTeX
@article{Wang2023,
  author = {Wang, Yaxian and Sun, Xipeng and Yang, Quanjun and Guo, Cheng},
  title = {Cucurbitacin IIb attenuates cancer cachexia induced skeletal muscle atrophy by regulating the IL ‐6/ STAT3 / FoxO signaling pathway},
  journal = {Phytotherapy Research},
  year = {2023},
  volume = {37},
  number = {8},
  pages = {3380--3393},
  doi = {10.1002/ptr.7811}
}
Start for free →